Literature DB >> 19608354

Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables.

Andy C Dean1, Edythe D London, Catherine A Sugar, Christina M R Kitchen, Aimee-Noelle Swanson, Keith G Heinzerling, Ari D Kalechstein, Steven Shoptaw.   

Abstract

Although some individuals who abuse methamphetamine have considerable cognitive deficits, no prior studies have examined whether neurocognitive functioning is associated with outcome of treatment for methamphetamine dependence. In an outpatient clinical trial of bupropion combined with cognitive behavioral therapy and contingency management (Shoptaw, S., Heinzerling, K.G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A.N., De La Garza, R., Newton, T., Ling, W., 2008. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 96, 222-232.), 60 methamphetamine-dependent adults completed three tests of reaction time and working memory at baseline. Other variables that were collected at baseline included measures of drug use, mood/psychiatric functioning, employment, social context, legal status, and medical status. We evaluated the relative predictive value of all baseline measures for treatment outcome using Classification and Regression Trees (CART; Breiman, L., Friedman, J.H., Olshen, R.A., Stone, C.J., 1984. Classification and Regression Trees. Wadsworth, Belmont, CA.), a nonparametric statistical technique that produces easily interpretable decision rules for classifying subjects that are particularly useful in clinical settings. Outcome measures were whether or not a participant completed the trial and whether or not most urine tests showed abstinence from methamphetamine abuse. Urine-verified methamphetamine abuse at the beginning of the study was the strongest predictor of treatment outcome; two psychosocial measures (e.g., nicotine dependence and Global Assessment of Functioning) also offered some predictive value. A few reaction time and working memory variables were related to treatment outcome, but these cognitive measures did not significantly aid prediction after adjusting for methamphetamine usage at the beginning of the study. On the basis of these findings, we recommend that research groups seeking to identify new predictors of treatment outcome compare the predictors to methamphetamine usage variables to assure that unique predictive power is attained.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608354      PMCID: PMC2754143          DOI: 10.1016/j.drugalcdep.2009.06.008

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  32 in total

1.  Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence.

Authors:  Adrianna Mendrek; John Monterosso; Sara L Simon; Murray Jarvik; Arthur Brody; Richard Olmstead; Catherine P Domier; Mark S Cohen; Monique Ernst; Edythe D London
Journal:  Addict Behav       Date:  2005-07-11       Impact factor: 3.913

2.  Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction.

Authors:  Antonio Verdejo-García; Antoine Bechara; Emily C Recknor; Miguel Pérez-García
Journal:  J Int Neuropsychol Soc       Date:  2006-05       Impact factor: 2.892

3.  Two-year outcomes of treatment for methamphetamine use.

Authors:  Mary-Lynn Brecht; Lisa Greenwell; Christina von Mayrhauser; M Douglas Anglin
Journal:  J Psychoactive Drugs       Date:  2006-11

Review 4.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

Review 5.  A systematic review of cognitive and behavioural therapies for methamphetamine dependence.

Authors:  Nicole K Lee; Richard A Rawson
Journal:  Drug Alcohol Rev       Date:  2008-05

6.  Neuropsychological function and delay discounting in methamphetamine-dependent individuals.

Authors:  William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

7.  Cognitive deficits predict low treatment retention in cocaine dependent patients.

Authors:  Efrat Aharonovich; Deborah S Hasin; Adam C Brooks; Xinhua Liu; Adam Bisaga; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2005-09-19       Impact factor: 4.492

8.  Methamphetamine treatment: trends and predictors of retention and completion in a large state treatment system (1992-2002).

Authors:  Mary-Lynn Brecht; Lisa Greenwell; M Douglas Anglin
Journal:  J Subst Abuse Treat       Date:  2005-12

9.  Attentional control and brain metabolite levels in methamphetamine abusers.

Authors:  Ruth Salo; Thomas E Nordahl; Yutaka Natsuaki; Martin H Leamon; Gantt P Galloway; Christy Waters; Charles D Moore; Michael H Buonocore
Journal:  Biol Psychiatry       Date:  2006-11-09       Impact factor: 13.382

10.  Predicting in-treatment performance and post-treatment outcomes in methamphetamine users.

Authors:  Maureen P Hillhouse; Patricia Marinelli-Casey; Rachel Gonzales; Alfonso Ang; Richard A Rawson
Journal:  Addiction       Date:  2007-04       Impact factor: 6.526

View more
  16 in total

Review 1.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

2.  Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.

Authors:  Aaron C Lim; Erica N Grodin; Rejoyce Green; Alexandra Venegas; Lindsay R Meredith; Kelly E Courtney; Nathasha R Moallem; Philip Sayegh; Edythe D London; Lara A Ray
Journal:  Am J Drug Alcohol Abuse       Date:  2020-04-28       Impact factor: 3.829

3.  Factors associated with caregiver stability in permanent placements: a classification tree approach.

Authors:  Laura J Proctor; Katherine Van Dusen Randazzo; Alan J Litrownik; Rae R Newton; Inger P Davis; Miguel Villodas
Journal:  Child Abuse Negl       Date:  2011-06-08

4.  Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence.

Authors:  Ryan Cook; Brendan Quinn; Keith Heinzerling; Steve Shoptaw
Journal:  Addiction       Date:  2017-02-16       Impact factor: 6.526

5.  Striatum and insula dysfunction during reinforcement learning differentiates abstinent and relapsed methamphetamine-dependent individuals.

Authors:  Jennifer L Stewart; Colm G Connolly; April C May; Susan F Tapert; Marc Wittmann; Martin P Paulus
Journal:  Addiction       Date:  2013-12-15       Impact factor: 6.526

Review 6.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

7.  Boundary conditions of methamphetamine craving.

Authors:  Richard B Lopez; Chukwudi Onyemekwu; Carl L Hart; Kevin N Ochsner; Hedy Kober
Journal:  Exp Clin Psychopharmacol       Date:  2015-08-24       Impact factor: 3.157

8.  Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use.

Authors:  Keith G Heinzerling; Aimee-Noelle Swanson; Timothy M Hall; Yi Yi; Yingnian Wu; Steven J Shoptaw
Journal:  Addiction       Date:  2014-08-05       Impact factor: 6.526

9.  Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.

Authors:  Matthew Brensilver; Keith G Heinzerling; Aimee-Noelle Swanson; Steven J Shoptaw
Journal:  Exp Clin Psychopharmacol       Date:  2012-08-06       Impact factor: 3.157

10.  Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.

Authors:  Larissa J Mooney; Maureen P Hillhouse; Christie Thomas; Alfonso Ang; Gaurav Sharma; Garth Terry; Linda Chang; Robrina Walker; Madhukar Trivedi; David Croteau; Steven Sparenborg; Walter Ling
Journal:  J Addict Med       Date:  2016 Jul-Aug       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.